Argos Therapeutics, Inc. is developing fully personalized immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform that we believe can tackle a wide range of cancers and infectious diseases.
Argos Therapeutics to Present at the 13th Annual BIO Investor Forum
Argos Therapeutics Enters Into $25 Million Venture Loan Facility Led by Horizon Technology Finance
Argos Therapeutics to Present at the 21st Annual BioCentury NewsMakers Conference